International contract research organisation Quintiles entered into a partnership with Queen Mary’s University of London. Since then the Prime Site has evolved and expanded across UCLPartners, the largest academic health science partnership in the UK.
Through the constituent NHS Trusts, Quintiles is able to place clinical trials in multiple hospital sites, with clinicians covering all therapeutic areas. This has increased access to the opportunities commercial clinical trials can offer for a large part of London. Through establishing close collaboration and process alignment, Quintiles has been able to overcome many of the traditional obstacles that beset clinical research. By building strong relationships and supporting investigator sites, the Quintiles UCLPartners Prime Site has achieved success in recruiting patients into trials and is currently one of the highest recruiting Quintiles Prime Sites globally.
In addition, working with the North Thames Clinical Research Network (CRN) has enabled Quintiles to significantly reduce contracting times and thereby optimize study start-up. The speed of set-up has enabled UCLPartners Prime Investigator sites to achieve first patient recruited in global studies. The performance of the UCLPartners Prime Site has contributed to the UK, and London in particular, remaining key contributors to global clinical research
“It is well recognized that there is significant pressure to speed the drug development process in order to develop treatments that enable people to live healthier lives,” said Lindy Jones, Chair European, Middle East and Africa Board, Quintiles.
“We are proud to be working with the team at UCL Partners to further enhance our ability to recruit patients and investigators who are critical to an efficient and effective drug development process. We have gone from strength to strength since this relationship began and we are proud of what we have achieved together, for the benefit of London as a whole.”